Cambium Bio Ltd CMB

ASX · Australia · Health Technology

AUD 0.5500+0.03 (+5.77%)

Market open· Oct 2, 2026, 1:29 AM UTC· AUD · Data may be delayed

Company news

Yahoo FinanceSep 16, 2026

Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease

Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financingSYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a clinical-stage regenerative medicine company developing biologic therapies for ophthalmology, today announced that it has secured an A$10.85 million funding package to initiate its pi

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.